Search
Search Results
-
-
Extracellular Vesicles and Pathological Cardiac Hypertrophy
Pathological cardiac hypertrophy is a well-recognized risk factor for cardiovascular diseases (CVDs). Although lots of efforts have been made to...
-
Benign Prostatic Hypertrophy
Benign prostatic hypertrophy is a very common anatomic–pathological condition of men after 45 years of age. It is estimated that around 50% of men...
-
-
Zonisamide attenuates pressure overload-induced myocardial hypertrophy in mice through proteasome inhibition
Myocardial hypertrophy is a pathological thickening of the myocardium which ultimately results in heart failure. We previously reported that...
-
Porcine Model of Hypertrophy-Independent Left Ventricular Stiffening via Repetitive Pressure Overload
Diastolic dysfunction arising from alterations in myocardial structure and/or function is a central component of several cardiovascular disorders,...
-
TRIM-containing 44 aggravates cardiac hypertrophy via TLR4/NOX4-induced ferroptosis
AbstractTRIM-containing 44 (TRIM44) is a promoter of multiple cancers. However, its role in cardiac hypertrophy has not been elucidated. This study...
-
-
Gut microbiota might mediate the benefits of high-fiber/acetate diet to cardiac hypertrophy mice
Continuously prolonged cardiac hypertrophy results in maladaptive myocardial remodeling, which affects cardiac function and can eventually lead to...
-
-
Cardiac hypertrophy that affects hyperthyroidism occurs independently of the NLRP3 inflammasome
Cardiac hypertrophy (CH) is an adaptive response to maintain cardiac function; however, persistent stress responses lead to contractile dysfunction...
-
Effect of diminazene on cardiac hypertrophy through mitophagy in rat models with hyperthyroidism induced by levothyroxine
Hyperthyroidism is associated with the alteration in molecular pathways involved in the regulation of mitochondrial mass and apoptosis, which...
-
JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit
Histone modification plays an important role in pathological cardiac hypertrophy and heart failure. In this study we investigated the role of a...
-
OSMR deficiency aggravates pressure overload-induced cardiac hypertrophy by modulating macrophages and OSM/LIFR/STAT3 signalling
BackgroundOncostatin M (OSM) is a secreted cytokine of the interleukin (IL)-6 family that induces biological effects by activating functional...
-
Decorin: a potential therapeutic candidate for ligamentum flavum hypertrophy by antagonizing TGF-β1
Ligamentum flavum hypertrophy (LFH) is the main physiological and pathological mechanism of lumbar spinal canal stenosis (LSCS). The specific...
-
miR-29b-3p Affects the Hypertrophy of Ligamentum Flavum in Lumbar Spinal Stenosis and its Mechanism
To explore the effect of miR-29b-3p on fibrosis and hypertrophy of ligamentum flavum (LF) in lumbar spinal stenosis (LSS) and its underlying...
-
Aberrant myonuclear domains and impaired myofiber contractility despite marked hypertrophy in MYMK-related, Carey-Fineman-Ziter Syndrome
Carey Fineman Ziter Syndrome (CFZS) is a rare autosomal recessive disease caused by mutations in the MYMK locus which encodes the protein, myomaker....
-
Polymorphic variants at NDUFC2, encoding a mitochondrial complex I subunit, associate with cardiac hypertrophy in human hypertension
BackgroundA dysfunction of NADH dehydrogenase, the mitochondrial Complex I (CI), associated with the development of left ventricular hypertrophy...
-
The Mechanism of the Anti-Cardiac Hypertrophy Effect of Glycyrrhizic Acid Is Related to Reducing STIM1-Dependent Store-Operated Calcium Entry
We explored the anti-cardiac hypertrophy mechanism of glycyrrhizic acid from the perspective of calcium regulation under pathological conditions. For...
-
Muscle hypertrophy and neuroplasticity in the small bowel in short bowel syndrome
Short bowel syndrome (SBS) is a severe, life-threatening condition and one of the leading causes of intestinal failure in children. Here we were...
